Meribank Biotech Co., Ltd (TPEX:4724)
Taiwan · Delayed Price · Currency is TWD 14.80
0.00 (0.00%)
At close: Feb 11, 2026
Meribank Biotech Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -66.84 | -94.71 | -125.35 | -102.13 | -99.19 | -54.46 |
Depreciation & Amortization | 137.44 | 83.22 | 34.28 | 32.16 | 29.47 | 23.77 |
Other Amortization | 0.45 | 0.81 | 2.25 | - | - | - |
Loss (Gain) From Sale of Assets | -0.01 | -0.01 | -0.07 | - | - | - |
Asset Writedown & Restructuring Costs | 0.86 | - | 5.67 | - | - | -5.86 |
Loss (Gain) From Sale of Investments | -2.84 | -2.72 | - | -5.79 | -0.18 | - |
Loss (Gain) on Equity Investments | 10.12 | 11.93 | 5.41 | 5.42 | 4.51 | 0.93 |
Stock-Based Compensation | 6 | 2.51 | 1.17 | 0.02 | 0.34 | 1.14 |
Provision & Write-off of Bad Debts | 3.79 | 1.23 | 3.84 | -0.59 | 5.28 | 4.14 |
Other Operating Activities | -9.15 | -7.28 | -4.14 | -1.45 | -0.37 | -8.15 |
Change in Accounts Receivable | -42.59 | -29.99 | 17.6 | -6.25 | -14.2 | 1.52 |
Change in Inventory | 0.43 | -4.34 | 1.54 | -4.84 | -0.67 | -0.29 |
Change in Accounts Payable | -4.36 | 1.85 | 3.29 | 2.3 | -0.24 | -0.34 |
Change in Unearned Revenue | 22.32 | 22.83 | 12.22 | 10.52 | 33.6 | 56.08 |
Change in Other Net Operating Assets | 0.64 | -23.42 | 12.58 | 29.31 | 18.66 | -36.24 |
Operating Cash Flow | 56.25 | -38.09 | -29.7 | -41.33 | -23 | -17.74 |
Capital Expenditures | -20.92 | -248.61 | -5.8 | -4.15 | -7.21 | -7.32 |
Sale of Property, Plant & Equipment | 0.01 | 0.01 | - | - | - | - |
Cash Acquisitions | 15.44 | 15.44 | -4.42 | -1.27 | - | - |
Sale (Purchase) of Intangibles | -0.45 | -95.58 | -0.88 | -0.09 | -0.31 | -0.21 |
Investment in Securities | 85.51 | -14.49 | 83.62 | -23.03 | -75.83 | 47.2 |
Other Investing Activities | -18.49 | -19.23 | -24.37 | -16.46 | -34.72 | -15.49 |
Investing Cash Flow | 59.96 | -362.46 | 48.15 | -45.01 | -118.07 | 24.18 |
Long-Term Debt Issued | - | 175 | - | - | - | - |
Long-Term Debt Repaid | - | -38.76 | -22.78 | -20.34 | -17.98 | -11.99 |
Net Debt Issued (Repaid) | -61.8 | 136.24 | -22.78 | -20.34 | -17.98 | -11.99 |
Issuance of Common Stock | - | - | 311.6 | - | 300 | 1.23 |
Other Financing Activities | 16.64 | 29.94 | 7.03 | -0.32 | -0.2 | 0.55 |
Financing Cash Flow | -45.16 | 166.17 | 295.85 | -20.66 | 281.82 | -10.22 |
Net Cash Flow | 70.43 | -234.37 | 314.3 | -106.99 | 140.76 | -3.77 |
Free Cash Flow | 35.33 | -286.7 | -35.5 | -45.48 | -30.2 | -25.05 |
Free Cash Flow Margin | 7.26% | -78.24% | -15.15% | -25.25% | -18.52% | -12.89% |
Free Cash Flow Per Share | 0.40 | -3.60 | -0.56 | -0.72 | -0.50 | -0.48 |
Cash Interest Paid | 20.38 | 10.7 | 0.85 | 0.99 | 1.13 | 0.74 |
Cash Income Tax Paid | 0.01 | 0.03 | - | - | - | - |
Levered Free Cash Flow | 44.09 | -330.4 | -11.46 | -43.73 | -55.04 | -27.46 |
Unlevered Free Cash Flow | 56.83 | -323.71 | -10.93 | -43.12 | -54.33 | -27 |
Change in Working Capital | -23.57 | -33.06 | 47.23 | 31.04 | 37.15 | 20.75 |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.